This is a phase-I, open-label, single-dose, dose-escalation, multicenter study of the effect of hu1124 on approximately 4-6 patients with moderate to severe plaque psoriasis. Patients will receive one intravenous infusion and will be assessed by clinical and laboratory examination for evidence of toxicity and biologic response.
Showing the most recent 10 out of 1380 publications